Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

T R Petersen; S Buus; S Brunak; Mogens Holst Nissen; L A Sherman; M H Claesson

Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

T R Petersen, S Buus, S Brunak, Mogens Holst Nissen, L A Sherman, M H Claesson

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

38 Citationer (Scopus)

Abstract

Udgivelsesdato: 2001-Apr

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Immunology
Vol/bind	53
Udgave nummer	4
Sider (fra-til)	357-64
Antal sider	7
ISSN	0300-9475
Status	Udgivet - 2001

Bibliografisk note

Keywords: Amino Acid Sequence; Amino Acid Substitution; Animals; Binding Sites; Carrier Proteins; Cell Line; Cross Reactions; Cytotoxicity, Immunologic; Epitopes; HLA-A2 Antigen; Humans; Immunization; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligopeptides; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53

Citationsformater

@article{a191daf0ba3011ddae57000ea68e967b,

title = "Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.",

abstract = "The replacement of a suboptimal amino acid in a primary anchor position with an optimal residue improves human leucocyte antigen (HLA) binding and immunogenicity, while maintaining cytotoxic T lymphocyte (CTL) specificity. Using a neural network capable of performing quantitative predictions of peptide binding to HLA-A2 molecules, we identified three p53 protein-derived nonamer peptides with intermediate binding owing to suboptimal amino acids in the P2 anchor position. These peptides were synthesized along with the corresponding analogs, where the natural P2 residue had been replaced with the optimal leucine residue. All three modified peptides bound to and more efficiently stabilized HLA-A2 molecules than the corresponding nonmodified peptides. The HLA-A2 transgenic mice were used for immunization. Two of the epitopes were more immunogenic in their modified than in their natural versions. The CTLs raised against the modified peptides efficiently killed the target cells pulsed with the corresponding native peptide. In terms of sensitizing the targets cells for the CTL killing, the modified peptides were more efficient than native peptides. Finally, the CTLs induced by modified peptide killed HLA-A2 transgenic mouse fibrosarcoma cells transfected with human p53 DNA. The data suggest that modified self-peptides derived from overexpressed tumour-associated proteins can be used in vaccine development against cancer, and that quantitative predictions of HLA binding is of value in the rational selection and improvement of target epitopes recognized by CTLs.",

author = "Petersen, {T R} and S Buus and S Brunak and Nissen, {Mogens Holst} and Sherman, {L A} and Claesson, {M H}",

note = "Keywords: Amino Acid Sequence; Amino Acid Substitution; Animals; Binding Sites; Carrier Proteins; Cell Line; Cross Reactions; Cytotoxicity, Immunologic; Epitopes; HLA-A2 Antigen; Humans; Immunization; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligopeptides; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53",

year = "2001",

language = "English",

volume = "53",

pages = "357--64",

journal = "Scandinavian Journal of Immunology, Supplement",

issn = "0301-6323",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

AU - Petersen, T R

AU - Buus, S

AU - Brunak, S

AU - Nissen, Mogens Holst

AU - Sherman, L A

AU - Claesson, M H

N1 - Keywords: Amino Acid Sequence; Amino Acid Substitution; Animals; Binding Sites; Carrier Proteins; Cell Line; Cross Reactions; Cytotoxicity, Immunologic; Epitopes; HLA-A2 Antigen; Humans; Immunization; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligopeptides; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53

PY - 2001

Y1 - 2001

N2 - The replacement of a suboptimal amino acid in a primary anchor position with an optimal residue improves human leucocyte antigen (HLA) binding and immunogenicity, while maintaining cytotoxic T lymphocyte (CTL) specificity. Using a neural network capable of performing quantitative predictions of peptide binding to HLA-A2 molecules, we identified three p53 protein-derived nonamer peptides with intermediate binding owing to suboptimal amino acids in the P2 anchor position. These peptides were synthesized along with the corresponding analogs, where the natural P2 residue had been replaced with the optimal leucine residue. All three modified peptides bound to and more efficiently stabilized HLA-A2 molecules than the corresponding nonmodified peptides. The HLA-A2 transgenic mice were used for immunization. Two of the epitopes were more immunogenic in their modified than in their natural versions. The CTLs raised against the modified peptides efficiently killed the target cells pulsed with the corresponding native peptide. In terms of sensitizing the targets cells for the CTL killing, the modified peptides were more efficient than native peptides. Finally, the CTLs induced by modified peptide killed HLA-A2 transgenic mouse fibrosarcoma cells transfected with human p53 DNA. The data suggest that modified self-peptides derived from overexpressed tumour-associated proteins can be used in vaccine development against cancer, and that quantitative predictions of HLA binding is of value in the rational selection and improvement of target epitopes recognized by CTLs.

AB - The replacement of a suboptimal amino acid in a primary anchor position with an optimal residue improves human leucocyte antigen (HLA) binding and immunogenicity, while maintaining cytotoxic T lymphocyte (CTL) specificity. Using a neural network capable of performing quantitative predictions of peptide binding to HLA-A2 molecules, we identified three p53 protein-derived nonamer peptides with intermediate binding owing to suboptimal amino acids in the P2 anchor position. These peptides were synthesized along with the corresponding analogs, where the natural P2 residue had been replaced with the optimal leucine residue. All three modified peptides bound to and more efficiently stabilized HLA-A2 molecules than the corresponding nonmodified peptides. The HLA-A2 transgenic mice were used for immunization. Two of the epitopes were more immunogenic in their modified than in their natural versions. The CTLs raised against the modified peptides efficiently killed the target cells pulsed with the corresponding native peptide. In terms of sensitizing the targets cells for the CTL killing, the modified peptides were more efficient than native peptides. Finally, the CTLs induced by modified peptide killed HLA-A2 transgenic mouse fibrosarcoma cells transfected with human p53 DNA. The data suggest that modified self-peptides derived from overexpressed tumour-associated proteins can be used in vaccine development against cancer, and that quantitative predictions of HLA binding is of value in the rational selection and improvement of target epitopes recognized by CTLs.

M3 - Journal article

C2 - 11285115

VL - 53

SP - 357

EP - 364

JO - Scandinavian Journal of Immunology, Supplement

JF - Scandinavian Journal of Immunology, Supplement

SN - 0301-6323

IS - 4

ER -